Oslo, Norway, April 28, 2021 - Vaccibody AS, a clinical-stage biopharmaceutical
company dedicated to the discovery and development of vaccines and novel
immunotherapies, announced today the appointment of Harald Gurvin as the
Company's Chief Financial Officer (CFO).
Harald Gurvin (47) has as a strong track-record and financial background with
many years of experience in large international companies.
Harald Gurvin comes to Vaccibody from a position as CFO in Flex LNG, a company
owning and operating LNG (liquefied natural gas) carriers and listed on both the
New York Stock Exchange and the Oslo Stock Exchange. Prior to Flex LNG, he was
CFO in SFL Corporation Limited (the former Ship Finance International Limited),
a leading international ship and rig owning company listed on the New York Stock
Exchange. Harald Gurvin holds a M.Sc. degree in Shipping, Trade and Finance from
CASS Business School, and a M.Sc. degree in in Marine Engineering and Naval
Architecture from the Norwegian University of Sciences and Technology (NTNU).
Chief Executive Officer of Vaccibody, Michael Engsig, states: "I am excited to
announce that Harald Gurvin will join our leadership team as Chief Financial
Officer. We have conducted an extensive international search for a leader to
bring onboard a very comprehensive international financial skillset. In his
previous role, he was responsible for the listing process on the New York Stock
Exchange. This is a unique experience that is very relevant in connection with
Vaccibody's capital market strategy which includes exploration of a potential
listing on Nasdaq Global Market in the United States."
Harald Gurvin will commence his new role at Vaccibody on May 3, 2021.
Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the
discovery and development of vaccines and novel immunotherapies. The Company
develops vaccines for the treatment cancer and infectious diseases. Vaccibody's
vaccine technology specifically targets antigens to Antigen Presenting Cells,
which are essential for inducing rapid, strong and long-lasting antigen-specific
immune responses and elicit efficacious clinical responses. Its lead product
candidates include VB10.NEO, a cancer neoantigen vaccine, which is exclusively
outlicensed to Genentech and is in phase I/IIa clinical trial for the treatment
of melanoma, lung- , head and neck, renal-, and bladder cancer